Related references
Note: Only part of the references are listed.The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome
Mei-Jou Chen et al.
HUMAN REPRODUCTION (2008)
Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome
Sophie Catteau-Jonard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome
Lisa J. Moran et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology
Aykut Bayrak et al.
FERTILITY AND STERILITY (2007)
Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries
Laura Pellatt et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The impact of obesity on reproduction in women with polycystic ovary syndrome
R. Pasquali et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2006)
Obesity and polycystic ovary syndrome
T. M. Barber et al.
CLINICAL ENDOCRINOLOGY (2006)
Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome
P Pigny et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Anti-Mullerian hormone: a new marker for ovarian function
JA Visser et al.
REPRODUCTION (2006)
Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome
T Piltonen et al.
HUMAN REPRODUCTION (2005)
Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism
T Eldar-Geva et al.
HUMAN REPRODUCTION (2005)
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
R Fleming et al.
FERTILITY AND STERILITY (2005)
The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest
S Jonard et al.
HUMAN REPRODUCTION UPDATE (2004)
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation
A La Marca et al.
HUMAN REPRODUCTION (2004)
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
BCJM Fauser et al.
HUMAN REPRODUCTION (2004)
Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age
JSE Laven et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet
PG Crosignani et al.
HUMAN REPRODUCTION (2003)
Assessing menstrual cycles with urinary hormone assays
N Santoro et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome
LJ Moran et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation
R Fanchin et al.
HUMAN REPRODUCTION (2003)
Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: Relationship to the ovarian follicle excess and to the follicular arrest
P Pigny et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women
CL Cook et al.
FERTILITY AND STERILITY (2002)
Share Paper
